04:38 GMT22 January 2021
Listen Live
    World
    Get short URL
    by
    7291
    Subscribe

    Sputnik V, developed by Russia's Gamaleya Research Institute in conjunction with the Russian Direct Investment Fund (RDIF), was 90 percent effective in ongoing clinical trials after three control points, according to data published in December.

    Russia will submit its Sputnik V vaccine for EU approval next month, the head of the Russian Direct Investment Fund Kirill Dmitriev told Reuters on Thursday.

    "We will have some discussions, already, on 19 January. And we will go through all of the process by submitting all of the documents to EMA [European Medicines Agency] in February of this year. We will share all of the data", Dmitriev said in a Reuters Next interview.

    According to Dmitriev, the vaccine will be registered in nine other countries this month and will be produced in seven nations. He estimated that the fund will arrange export deals with interested parties over the next six to nine months and expects the vaccine ultimately to have about 25 percent of the global market share.

    He stated that 95 percent of Sputnik V export deals will be made by manufacturers outside Russia.

    The RDIF boss added that the peer-reviewed results of the vaccine demonstrating its high efficacy will be available soon.

    In August, Russia became the first country to register a COVID-19 vaccine, which was named Sputnik V. The clinical trials of the jab have shown an efficacy rate of more than 90 percent.

    Sputnik V was developed by the Gamaleya Research Institute and marketed abroad by the RDIF.

    Tags:
    approval, vaccine, Sputnik V
    Community standardsDiscussion